The Interplay Between Epitranscriptomic RNA Modifications and Neurodegenerative Disorders: Mechanistic Insights and Potential Therapeutic Strategies

Overview

Journal Ibrain

Specialty Neurology

Date 2024 Dec 18

PMID 39691424

Authors

Muhammad Abu Talha Safdar Hashmi

Hooriya Fatima

Sadia Ahmad

Amna Rehman

Fiza Safdar

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative disorders encompass a group of age-related conditions characterized by the gradual decline in both the structure and functionality of the central nervous system (CNS). RNA modifications, arising from the epitranscriptome or RNA-modifying protein mutations, have recently been observed to contribute significantly to neurodegenerative disorders. Specific modifications like N6-methyladenine (m6A), N1-methyladenine (m1A), 5-methylcytosine (m5C), pseudouridine and adenosine-to-inosine (A-to-I) play key roles, with their regulators serving as crucial therapeutic targets. These epitranscriptomic changes intricately control gene expression, influencing cellular functions and contributing to disease pathology. Dysregulation of RNA metabolism, affecting mRNA processing and noncoding RNA biogenesis, is a central factor in these diseases. This review underscores the complex relationship between RNA modifications and neurodegenerative disorders, emphasizing the influence of RNA modification and the epitranscriptome, exploring the function of RNA modification enzymes in neurodegenerative processes, investigating the functional consequences of RNA modifications within neurodegenerative pathways, and evaluating the potential therapeutic advancements derived from assessing the epitranscriptome.

References

Hamma T, Ferre-DAmare A . Pseudouridine synthases. Chem Biol. 2006; 13(11):1125-35. DOI: 10.1016/j.chembiol.2006.09.009. View

Koch J, Tatenhorst L, Roser A, Saal K, Tonges L, Lingor P . ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018; 189:1-21. DOI: 10.1016/j.pharmthera.2018.03.008. View

Jellinger K . Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna). 2009; 116(9):1111-62. DOI: 10.1007/s00702-009-0240-y. View

He P, He C . m A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021; 40(3):e105977. PMC: 7849164. DOI: 10.15252/embj.2020105977. View

Ivanov A, Memczak S, Wyler E, Torti F, Porath H, Orejuela M . Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015; 10(2):170-7. DOI: 10.1016/j.celrep.2014.12.019. View

Nie F, Tang Q, Liu Y, Qin H, Liu S, Wu M . RNAME: A comprehensive database of RNA modification enzymes. Comput Struct Biotechnol J. 2022; 20:6244-6249. PMC: 9678767. DOI: 10.1016/j.csbj.2022.11.022. View

Hallacli E, Kayatekin C, Nazeen S, Wang X, Sheinkopf Z, Sathyakumar S . The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell. 2022; 185(12):2035-2056.e33. PMC: 9394447. DOI: 10.1016/j.cell.2022.05.008. View

Du B, Zhang Y, Liang M, Du Z, Li H, Fan C . N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions. Aging (Albany NY). 2021; 13(16):20716-20737. PMC: 8436914. DOI: 10.18632/aging.203457. View

Song T, Lv S, Li N, Zhao X, Ma X, Yan Y . Versatile functions of RNA m6A machinery on chromatin. J Mol Cell Biol. 2022; 14(3). PMC: 9264158. DOI: 10.1093/jmcb/mjac011. View

10.

Li J, Zhang H, Wang H . N-methyladenosine modification in cancer biology: Current status and future perspectives. Comput Struct Biotechnol J. 2022; 20:6578-6585. PMC: 9712505. DOI: 10.1016/j.csbj.2022.11.045. View

11.

Mugridge J, Coller J, Gross J . Structural and molecular mechanisms for the control of eukaryotic 5'-3' mRNA decay. Nat Struct Mol Biol. 2018; 25(12):1077-1085. DOI: 10.1038/s41594-018-0164-z. View

12.

Hawkins B, Davis T . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57(2):173-85. DOI: 10.1124/pr.57.2.4. View

13.

Mahmood A, Shah A, Umair M, Wu Y, Khan A . Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to step-up. Clin Genet. 2021; 100(6):659-677. DOI: 10.1111/cge.14019. View

14.

He H, Zhang Q, Liao J, Lei J, Luo M, Huang J . METTL14 is decreased and regulates m A modification of α-synuclein in Parkinson's disease. J Neurochem. 2023; 166(3):609-622. DOI: 10.1111/jnc.15882. View

15.

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

16.

Tuorto F, Liebers R, Musch T, Schaefer M, Hofmann S, Kellner S . RNA cytosine methylation by Dnmt2 and NSun2 promotes tRNA stability and protein synthesis. Nat Struct Mol Biol. 2012; 19(9):900-5. DOI: 10.1038/nsmb.2357. View

17.

Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H . Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012; 45(3):1121-8. DOI: 10.1016/j.nbd.2011.12.033. View

18.

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

19.

Gamez-Valero A, Guisado-Corcoll A, Herrero-Lorenzo M, Solaguren-Beascoa M, Marti E . Non-Coding RNAs as Sensors of Oxidative Stress in Neurodegenerative Diseases. Antioxidants (Basel). 2020; 9(11). PMC: 7695195. DOI: 10.3390/antiox9111095. View

20.

Zhai J, Koh J, Soong T . RNA editing of ion channels and receptors in physiology and neurological disorders. Oxf Open Neurosci. 2024; 1:kvac010. PMC: 11003377. DOI: 10.1093/oons/kvac010. View